Reduced expression of Rho guanine nucleotide dissociation inhibitor-α modulates the cytotoxic effect of busulfan in HEK293 cells

Anti-Cancer Drugs

Volumn 18, Issue 3, 2007, Pages 333-340

  Reimer, Janka ^a   Bien, Sandra ^a   Sonnemann, Jürgen ^a   Beck, James F ^a   Wieland, Thomas ^b   Kroemer, Heyo K ^a   Ritter, Christoph A ^a,c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute of Pharmacy   (Germany)

Author keywords

Apoptosis; Busulfan; Cytotoxicity; RhoGDI ; Small interfering RNA

Indexed keywords

BUSULFAN; CASPASE 3; DIMETHYL SULFOXIDE; DOXORUBICIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; MESSENGER RNA; PACLITAXEL; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL STIMULATION; CELL STRAIN HEK293; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; EMBRYO; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BUSULFAN; CASPASE 3; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; ENZYME INDUCTION; FLUORESCENT ANTIBODY TECHNIQUE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; RHO GTP-BINDING PROTEINS; RNA, NEOPLASM; RNA, SMALL INTERFERING; SPECTROMETRY, FLUORESCENCE;

EID: 33846685107     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328011fd7f     Document Type: Article

References (23)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347-1353.
2. Josvasen N, Boyum A. Haematopoiesis in busulphan-treated mice. A comparison between two different stem cell assays. Scand J Haematol 1973; 11:78-86.
3. Dunn CD. Capacity of rat haemopoietic colony-forming units to produce differentiated progeny. Acta Haematol 1974; 51:101-112.
4. Millar BC, Tilby MJ, Ormerod MG, Payne AW, Jinks S, Loverock PS. Comparative studies of total cross-linking, cell survival and cell cycle perturbations in Chinese hamster cells treated with alkylating agents in vitro. Biochem Pharmacol 1986; 35:1163-1169.
5. 2-arrest and induces tissue factor expression. Br J Pharmacol 2002; 137:1100-1106.
6. Hassan Z, Hassan M, Hellstrom-Lindberg E. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia 2001; 15:1240-1247.
7. Muris DF, Verschoor T, Divecha N, Michalides RJ. Constitutive active GTPases, Rac and Cdc42 are associated with endoreplication in PAE cells. Eur J Cancer 2002; 38:1775-1782.
8. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001; 165:1-10.
9. Ridley AJ. Rho proteins and cancer. Breast Cancer Res Treat 2004; 84:13-19.
10. Fukumoto Y, Kaibuchi K, Hori Y, Fujioka H, Araki S, Ueda T, et al. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 1990; 5:1321-1328.
11. Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci U S A 1993; 90:7568-7572.
12. Zalcman G, Closson V, Camonis J, Honore N, Rousseau-Merck MF, Tavitian A, et al. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J Biol Chem 1996; 271:30366-30374.
13. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2:76-84.
14. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, Yazidi-Belkoura I, Nurcombe V, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001; 1:1216-1232.
15. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003; 63:6928-6934.
16. Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 2005; 65:6054-6062.
17. Fisher VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan. Oncol Nurs Forum 2006; 33:E36-E43.
18. Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001; 8:746-750.
19. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005; 15:356-363.
20. Togawa A, Miyoshi J, Ishizaki H, Tanaka M, Takakura A, Nishioka H, et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 1999; 18:5373-5380.
21. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002; 87:635-644.
22. Poland J, Sinha P, Siegert A, Schnolzer M, Korf U, Hauptmann S. Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture. Electrophoresis 2002; 23:1174-1184.
23. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 1999; 20:2961-2969.